Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>BioNTech, a pioneering biopharmaceutical company, revealed their fourth quarter and full year financial results for 2024, along with strategic priorities moving into 2025.</li>
<li>The company remains steadfast in its mission to leverage its immunotherapy and architectural prowess to tackle diseases, especially cancer and infectious diseases like COVID-19.</li>
<li>In 2024, BioNTech reported revenues of approximately EUR 2.8 billion, aligning with the midpoint of its guidance, although this represents a decline from the previous year, attributed to reduced COVID-19 vaccine demand.</li>
</ul>


BioNTech, a pioneering biopharmaceutical company, revealed their fourth quarter and full year financial results for 2024, along with strategic priorities moving into 2025.
The company remains steadfast in its mission to leverage its immunotherapy and architectural prowess to tackle diseases, especially cancer and infectious diseases like COVID-19.
In 2024, BioNTech reported revenues of approximately EUR 2.8 billion, aligning with the midpoint of its guidance, although this represents a decline from the previous year, attributed to reduced COVID-19 vaccine demand.


How BioNTech’s Growing Oncology Pipeline Could Reshape Its Future!

<ul>
<li>BioNTech's third quarter of 2024 earnings report reflects a balanced mix of progress in its oncology pipeline and its ongoing responses to the changing COVID-19 landscape.</li>
<li>The company has achieved notable advancements in both its COVID-19 vaccine franchise and its oncology development programs, showcasing a commitment to innovation while navigating the complexities of the healthcare market.</li>
<li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li>
</ul>


BioNTech's third quarter of 2024 earnings report reflects a balanced mix of progress in its oncology pipeline and its ongoing responses to the changing COVID-19 landscape.
The company has achieved notable advancements in both its COVID-19 vaccine franchise and its oncology development programs, showcasing a commitment to innovation while navigating the complexities of the healthcare market.
Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.


BioNTech: Strategic Partnerships & Innovation Driving Our ‘Outperform’ Rating!

<ul>
<li>BioNTech's second quarter of 2024 earnings revealed a company navigating both ongoing strides in its primary COVID-19 vaccine franchise and advancing its footprint in the oncology sector.</li>
<li>The call demonstrated BioNTech's commitment to expanding its product offerings while managing the shifts in market demands and regulatory landscapes.</li>
<li>For the second quarter of 2024, the total revenue reported by BioNTech was approximately EUR 129 million, a decline from EUR 168 million in the same quarter the previous year.</li>
</ul>


BioNTech's second quarter of 2024 earnings revealed a company navigating both ongoing strides in its primary COVID-19 vaccine franchise and advancing its footprint in the oncology sector.
The call demonstrated BioNTech's commitment to expanding its product offerings while managing the shifts in market demands and regulatory landscapes.
For the second quarter of 2024, the total revenue reported by BioNTech was approximately EUR 129 million, a decline from EUR 168 million in the same quarter the previous year.


BioNTech SE: Expansion of MRNA Technology Applications & Major Drivers

<ul>
<li>BioNTech's First Quarter 2024 Earnings Call highlighted a strategic focus on their late-stage oncology pipeline and continued initiatives surrounding their COVID-19 vaccine offerings.</li>
<li>The company's advancement in multiple pivotal Phase III clinical trials, primarily in oncology, and preparation for upcoming new strains of COVID-19 vaccines suggests a pivotal transformation period.</li>
<li>Positively, BioNTech's progression in oncology is notable with its comprehensive approach of integrating multiple therapeutic solutions.</li>
</ul>


BioNTech's First Quarter 2024 Earnings Call highlighted a strategic focus on their late-stage oncology pipeline and continued initiatives surrounding their COVID-19 vaccine offerings.
The company's advancement in multiple pivotal Phase III clinical trials, primarily in oncology, and preparation for upcoming new strains of COVID-19 vaccines suggests a pivotal transformation period.
Positively, BioNTech's progression in oncology is notable with its comprehensive approach of integrating multiple therapeutic solutions.


BioNTech SE: Expansion into Oncology and Cancer Therapies & Other Major Drivers

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Duality Biotherapeutics / Equity Capital Markets

<ul>
<li>Duality, a China-based clinical-stage biotechnology company, launched its IPO to raise up to US$200m via a Hong Kong listing.</li>
<li>We look at the deal dynamics and latest developments in the biotech sector.</li>
<li>The deal initially presented upside for investors but there’s a portion of its valuation now at risk due to the latest development.</li>
</ul>


Duality, a China-based clinical-stage biotechnology company, launched its IPO to raise up to US$200m via a Hong Kong listing.
We look at the deal dynamics and latest developments in the biotech sector.
The deal initially presented upside for investors but there’s a portion of its valuation now at risk due to the latest development.


Duality Biotherapeutics (映恩生物) IPO: Valuation Upside at Risk

Germany

BioNTech SE provides biotechnological solutions. The Company develops various types of treatments for cancer patients' tumors. BioNTech serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioNTech (BNTX US)

How BioNTech’s Growing Oncology Pipeline Could Reshape Its Future!

BioNTech, a pioneering biopharmaceutical company, revealed their fourth quarter and full year financial results for 2024, along with strategic...

Baptista Research

BioNTech: Strategic Partnerships & Innovation Driving Our ‘Outperform’ Rating!

BioNTech's third quarter of 2024 earnings report reflects a balanced mix of progress in its oncology pipeline and its ongoing responses to the...

Baptista Research

BioNTech SE: Expansion of MRNA Technology Applications & Major Drivers

BioNTech's second quarter of 2024 earnings revealed a company navigating both ongoing strides in its primary COVID-19 vaccine franchise and...

Baptista Research

BioNTech SE: Expansion into Oncology and Cancer Therapies & Other Major Drivers

BioNTech's First Quarter 2024 Earnings Call highlighted a strategic focus on their late-stage oncology pipeline and continued initiatives...

Baptista Research

Duality Biotherapeutics (映恩生物) IPO: Valuation Upside at Risk

We analyzed the dynamics of Duality Biotherapeutics' USD 200m Hong-Kong listing, and highlight how recent events put out valuation upside at risk.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)